Clinical trial
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the…
NCT00050102 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00050102 |
|---|---|
| Title | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma |
| Official title | A Randomized Study Comparing MDX-010 (CTLA-4) Alone or in Combination With DTIC in the Treatment of Patients With Chemotherapy Naїve Metastatic Melanoma. |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | MDX-010 (CTLA-4) |
| Start date | Oct 1, 2002 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Nov 22, 2002 |
| Last update posted | Jan 28, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: